Yi Luo

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding
    Omar L Francone
    Department of Atherosclerosis Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    J Lipid Res 50:546-55. 2009
  2. ncbi Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease
    Yi Luo
    Compound Safety Prediction, Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Toxicol Sci 129:346-62. 2012
  3. ncbi Cyclosporine A and palmitic acid treatment synergistically induce cytotoxicity in HepG2 cells
    Yi Luo
    Compound Safety Prediction Group, Pfizer Global Research and Development, Groton, CT 06340, USA
    Toxicol Appl Pharmacol 261:172-80. 2012
  4. ncbi Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes
    Yi Luo
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research Division, Pfizer Inc, Groton, CT 06340, USA
    J Pharmacol Exp Ther 332:1100-6. 2010
  5. ncbi Identification and characterization of dual inhibitors for phospholipid transfer protein and microsomal triglyceride transfer protein
    Yi Luo
    Department of Cardiovascular Metabolic and Endocrine Disease, Pfizer Global Research Division, Pfizer Inc, Groton, Connecticut 06340, USA
    J Pharmacol Exp Ther 335:653-8. 2010
  6. ncbi Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
    Yi Luo
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton New London Laboratories, Groton, CT 06340, USA zer com
    J Lipid Res 50:1581-8. 2009
  7. ncbi Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435
    B Ganesh Bhat
    Cardiovascular and Metabolic Diseases Discovery Research, Pfizer Inc, St Louis, MO 63167, USA
    J Lipid Res 44:1614-21. 2003
  8. ncbi Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice
    Lorraine Shelly
    Department of Cardiovascular, Metabolic, and Endocrine Diseases, Pfizer Global Research Division, Pfizer, Inc, Groton, CT 06340, USA
    J Lipid Res 49:773-81. 2008
  9. ncbi Chronic treatment with epoxyeicosatrienoic acids modulates insulin signaling and prevents insulin resistance in hepatocytes
    Jill E Skepner
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research Division, Pfizer Inc, Groton, CT 06340, USA
    Prostaglandins Other Lipid Mediat 94:3-8. 2011

Collaborators

Detail Information

Publications9

  1. ncbi The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding
    Omar L Francone
    Department of Atherosclerosis Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    J Lipid Res 50:546-55. 2009
    ..These studies suggest that the central hydrophobic tunnel that extends through the entire LOX-1 molecule is a key functional domain of the receptor and is critical for the recognition of modified LDL...
  2. ncbi Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease
    Yi Luo
    Compound Safety Prediction, Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Toxicol Sci 129:346-62. 2012
    ..Furthermore, this assay may be used to identify compounds that have higher safety risks in a population with metabolic syndrome...
  3. ncbi Cyclosporine A and palmitic acid treatment synergistically induce cytotoxicity in HepG2 cells
    Yi Luo
    Compound Safety Prediction Group, Pfizer Global Research and Development, Groton, CT 06340, USA
    Toxicol Appl Pharmacol 261:172-80. 2012
    ..Furthermore, hyperlipidemia/obesity resulting from immunosuppressive therapy may aggravate CsA-induced toxicity and worsen the outcome in transplant patients...
  4. ncbi Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes
    Yi Luo
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research Division, Pfizer Inc, Groton, CT 06340, USA
    J Pharmacol Exp Ther 332:1100-6. 2010
    ..These studies provided evidence that PLTP activity regulates apoB secretion and pharmacologic inhibition of PLTP may be a new therapy for dyslipidemia by reducing apoB secretion...
  5. ncbi Identification and characterization of dual inhibitors for phospholipid transfer protein and microsomal triglyceride transfer protein
    Yi Luo
    Department of Cardiovascular Metabolic and Endocrine Disease, Pfizer Global Research Division, Pfizer Inc, Groton, Connecticut 06340, USA
    J Pharmacol Exp Ther 335:653-8. 2010
    ..We conclude that MTP and PLTP may work coordinately in the process of hepatic apoB assembly and secretion. To avoid liver toxicity mediated by MTP inhibition, selective PLTP inhibitors should be pursued...
  6. ncbi Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
    Yi Luo
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton New London Laboratories, Groton, CT 06340, USA zer com
    J Lipid Res 50:1581-8. 2009
    ..Our data also suggest that LDLR protein regulation by PCSK9 has tissue specificity, with liver being the most responsive tissue...
  7. ncbi Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435
    B Ganesh Bhat
    Cardiovascular and Metabolic Diseases Discovery Research, Pfizer Inc, St Louis, MO 63167, USA
    J Lipid Res 44:1614-21. 2003
    ..These results suggest that specific inhibition of ASBT is a novel therapeutic approach for treatment of hypercholesterolemia resulting in a decreased risk for atherosclerosis...
  8. ncbi Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice
    Lorraine Shelly
    Department of Cardiovascular, Metabolic, and Endocrine Diseases, Pfizer Global Research Division, Pfizer, Inc, Groton, CT 06340, USA
    J Lipid Res 49:773-81. 2008
    ..Furthermore, plasma interleukin-6 levels are significantly lower in PLTP-deficient mice, indicating reduced systemic inflammation. These data suggest that PLTP appears to play a proatherogenic role in diet-induced hyperlipidemic mice...
  9. ncbi Chronic treatment with epoxyeicosatrienoic acids modulates insulin signaling and prevents insulin resistance in hepatocytes
    Jill E Skepner
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research Division, Pfizer Inc, Groton, CT 06340, USA
    Prostaglandins Other Lipid Mediat 94:3-8. 2011
    ..The requirement of chronic treatment with EETs suggests that the effects of EETs on insulin response may be indirect...